Genelux Corporation Common Stock

GNLXNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
2.93 USD
↘ 0.15 (4.87%)AT CLOSE (11:59 AM EDT)
3.17
↗ 0.24 (8.02%)
POST MARKET (AS OF 05:23 PM EDT)
Post Market
AS OF 05:23 PM EDT
3.17
↗ 0.24 (8.02%)
🔴Market: CLOSED
Open?$3.06
High?$3.07
Low?$2.89
Prev. Close?$3.08
Volume?166.2K
Avg. Volume?164.2K
VWAP?$2.96
Rel. Volume?1.01x
Bid / Ask
Bid?$2.15 × 100
Ask?$3.88 × 100
Spread?$1.73
Midpoint?$3.01
Valuation & Ratios
Market Cap?131.4M
Shares Out?44.8M
Float?38.2M
Float %?85.3%
P/E Ratio?N/A
P/B Ratio?5.73
EPS?-$0.75
Dividend?0.00%
Ex-Dividend?N/A

GNLX is currently priced at $2.93. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Furthermore, GNLX is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
26
Market Cap
131.4M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.genelux.com
Listed
2023-01-26
Address
2625 TOWNSGATE ROAD, SUITE 230
WESTLAKE VILLAGE, CA 91361
Phone: 805-267-9889
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
53
Piotroski F-Score?0/9Weak
Altman Z-Score?-7.11Distress
Confidence?50%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?7.74%Elevated
Short Interest?3.0M
Days to Cover?15.1
Free Float38.2M
Avg Daily Volume196.2K
Settlement Date2026-05-15
Financial Health
Current Ratio?3.68Strong
Quick Ratio?3.68Strong
Cash Ratio?1.28Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
32
5.73FAIR▾
P/S?
Peers
100
S&P
3
16,422.80HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
15,263.68HIGH▾
Returns & Efficiency
ROE?
S&P
3
-146.5%WEAK▾
ROA?
S&P
3
-103.7%WEAK▾
Cash Flow & Enterprise
FCF?$-27881000
Enterprise Value?$122.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist